Bristol Myers Squibb Presents Late-Breaking Phase 3 Data Demonstrating Health Status Benefits of Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy at American College of Cardiology�
Go back to Bristol Myers Squibb Presents Late-Breaking Phase 3 Data Demonstrating Health Status Benefits of Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy at American College of Cardiology�| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 47.18 -1.68 (3.44%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $48.86 | 52 Week High | $77.12 | |||
| Open | $47.39 | 52 Week Low | $49.03 | |||
| Day High | $47.50 | P/E | 30.64 | |||
| Day Low | $46.93 | EPS | $1.54 | |||
| Volume | 1,342,258 | |||||
